相关实验视频

Updated: Jun 17, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

接受低密集治疗的AML成人的遗传风险分类:2024年ELN建议:AML成人的遗传风险分类

Hartmut Döhner¹, Courtney D DiNardo², Frederick R Appelbaum³

¹Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.

|August 12, 2024

概括

欧洲白血病网络 (ELN) 对急性髓性白血病 (AML) 的分类需要更新. 为接受较少强度治疗的患者提出了一种新的遗传风险分类,改进了AML治疗策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

欧洲白血病网络 (ELN) 的遗传风险分类是急性髓性白血病 (AML) 管理的基础.
这些分类最初是从接受密集化疗方案的年轻成年人群中获得的.
最近的研究表明,不那么强烈的治疗方法可能会改变预后因素.

研究的目的:

建议修订欧洲白血病网络 (ELN) 的遗传风险分类.
专门解决急性髓性白血病 (AML) 患者接受较少强度治疗的需求.
为更广泛的AML患者队列增强风险分层和治疗指导.

主要方法:

对新出现的分析和临床数据的审查,这些数据来自于使用较少强度疗法治疗的患者.
对现有ELN分类与新患者数据进行比较分析.
拟议更新的遗传风险分层模型的开发.

主要成果:

现有的ELN遗传风险分类可能不准确地反映了接受低强度治疗的患者的结果.
在这个患者群体中观察到一组独特的遗传标记及其预后意义.
拟议的分类旨在提供更精确的风险评估.

结论:

适用于接受不那么密集治疗的AML患者,需要一个定制的欧洲白血病网 (ELN) 遗传风险分类.
这种调整将提高预后预测的准确性.
优化风险分层可以导致更个性化和更有效的AML治疗策略.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...